86 related articles for article (PubMed ID: 11529198)
1. Herpes vaccine encouraging.
AIDS Patient Care STDS; 2001 Jun; 15(6):342. PubMed ID: 11529198
[No Abstract] [Full Text] [Related]
2. Is herpes simplex virus type 1 (HSV-1) now more common than HSV-2 in first episodes of genital herpes?
Mertz GJ; Rosenthal SL; Stanberry LR
Sex Transm Dis; 2003 Oct; 30(10):801-2. PubMed ID: 14520182
[No Abstract] [Full Text] [Related]
3. A paradigm shift: vaccine-induced antibodies as an immune correlate of protection against herpes simplex virus type 1 genital herpes.
Awasthi S; Friedman HM
J Infect Dis; 2014 Mar; 209(6):813-5. PubMed ID: 24285847
[No Abstract] [Full Text] [Related]
4. Development of prophylactic vaccines for genital and neonatal herpes.
Jones CA; Cunningham AL
Expert Rev Vaccines; 2003 Aug; 2(4):541-9. PubMed ID: 14711338
[TBL] [Abstract][Full Text] [Related]
5. Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs.
Bourne N; Bravo FJ; Francotte M; Bernstein DI; Myers MG; Slaoui M; Stanberry LR
J Infect Dis; 2003 Feb; 187(4):542-9. PubMed ID: 12599070
[TBL] [Abstract][Full Text] [Related]
6. Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection.
Da Costa XJ; Morrison LA; Knipe DM
Virology; 2001 Sep; 288(2):256-63. PubMed ID: 11601897
[TBL] [Abstract][Full Text] [Related]
7. [Vaccines as an approach to the immunocorrection in herpetic infections].
Barinskiĭ IF; Alimbarova LM; Lazarenko AA; Makhmudov FR; Sergeev OV
Vopr Virusol; 2014; 59(1):5-11. PubMed ID: 25065139
[TBL] [Abstract][Full Text] [Related]
8. [Inactivated herpes simplex virus types 1 and 2 divaccine as an agent for effective immunoprophylaxis of recurrent genital herpes].
Barinskiĭ IF; Makhmudov FR
Vopr Virusol; 2010; 55(1):35-40. PubMed ID: 20364670
[TBL] [Abstract][Full Text] [Related]
9. A human papillomavirus type 16 vaccine.
Schrag SJ; Schuchat A; Schulkin J
N Engl J Med; 2003 Apr; 348(14):1402-5; author reply 1402-5. PubMed ID: 12678020
[No Abstract] [Full Text] [Related]
10. Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines.
Stanberry LR
Herpes; 2004 Aug; 11 Suppl 3():161A-169A. PubMed ID: 15319086
[TBL] [Abstract][Full Text] [Related]
11. Summaries for patients. Condom use and genital herpes.
Ann Intern Med; 2005 Nov; 143(10):I40. PubMed ID: 16287786
[No Abstract] [Full Text] [Related]
12. Vaccination strategies to prevent genital herpes and neonatal herpes simplex virus (HSV) disease.
Jones CA; Cunningham AL
Herpes; 2004 Apr; 11(1):12-7. PubMed ID: 15115632
[TBL] [Abstract][Full Text] [Related]
13. The Holy Grail: immune control of human herpes simplex virus infection and disease.
Cunningham AL; Mikloska Z
Herpes; 2001 Mar; 8 Suppl 1():6A-10A. PubMed ID: 11867028
[TBL] [Abstract][Full Text] [Related]
14. A tale of 2 alpha-herpesviruses: lessons for vaccinologists.
Rouse BT; Kaistha SD
Clin Infect Dis; 2006 Mar; 42(6):810-7. PubMed ID: 16477558
[TBL] [Abstract][Full Text] [Related]
15. Perceptions of parents seeking an experimental herpes simplex vaccine for their adolescent and preadolescent daughters.
Fowler SL; Dickey M; Kern P; Zimet GD; Rosenthal SL
Pediatr Infect Dis J; 2006 Aug; 25(8):747-8. PubMed ID: 16874178
[TBL] [Abstract][Full Text] [Related]
16. Immunobiology of herpes simplex virus (HSV) infections.
Corey L
Herpes; 2001 Mar; 8 Suppl 1():1A. PubMed ID: 11867026
[No Abstract] [Full Text] [Related]
17. Genital herpes vaccine shows limited promise.
Stephenson J
JAMA; 2000 Oct; 284(15):1913-4. PubMed ID: 11035871
[No Abstract] [Full Text] [Related]
18. An update on short-course episodic and prevention therapies for herpes genitalis.
Corey L; Bodsworth N; Mindel A; Patel R; Schacker T; Stanberry L
Herpes; 2007 Jun; 14 Suppl 1():5A-11A. PubMed ID: 17877886
[TBL] [Abstract][Full Text] [Related]
19. Testing for genital herpes: how, who, and why.
Wald A
Curr Clin Top Infect Dis; 2002; 22():166-80. PubMed ID: 12520653
[No Abstract] [Full Text] [Related]
20. Predicting the potential individual- and population-level effects of imperfect herpes simplex virus type 2 vaccines.
Schwartz EJ; Blower S
J Infect Dis; 2005 May; 191(10):1734-46. PubMed ID: 15838802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
